John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$510M |
| 2 |
Broadcom
AVGO
|
+$318M |
| 3 |
Marvell Technology
MRVL
|
+$290M |
| 4 |
Salesforce
CRM
|
+$263M |
| 5 |
Advanced Micro Devices
AMD
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$255M |
| 2 |
Progressive
PGR
|
+$244M |
| 3 |
Visa
V
|
+$238M |
| 4 |
Lam Research
LRCX
|
+$201M |
| 5 |
Elevance Health
ELV
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.88% |
| 2 | Healthcare | 13.28% |
| 3 | Financials | 10.32% |
| 4 | Industrials | 9.79% |
| 5 | Consumer Discretionary | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WHWK
2926
Whitehawk Therapeutics
WHWK
$278M
| $76.8K | ﹤0.01% |
43,158
-25,397
| -37% | -$66.3K |
|
2927
AerSale
ASLE
$268M
| $75.1K | ﹤0.01% |
+10,028
| New | +$71.7K |
|
2928
Vince Holding Corp
VNCE
$80.9M
| $74.2K | ﹤0.01% |
+38,635
| New | +$113K |
|
2929
CytomX Therapeutics
CTMX
$717M
| $74.1K | ﹤0.01% |
116,475
-204,292
| -64% | -$158K |
|
2930
Custom Truck One Source
CTOS
$2.22B
| $73.6K | ﹤0.01% |
17,448
+4,300
| +33% | +$20.8K |
|
|
LVTX
2931
DELISTED
LAVA Therapeutics
LVTX
| $73.3K | ﹤0.01% |
57,715
+8,943
| +18% | +$9.95K |
|
2932
Stem
STEM
$52.6M
| $72.9K | ﹤0.01% |
10,406
+70
| +0.7% | +$811 |
|
2933
TOP Financial Group
TOP
$2.01B
| $72.8K | ﹤0.01% |
11,747
+1,090
| +10% | +$7.49K |
|
2934
Tango Therapeutics
TNGX
$4.13B
| $72.5K | ﹤0.01% |
52,902
+7,906
| +18% | +$19.4K |
|
2935
ImmunityBio
IBRX
$8.03B
| $71.6K | ﹤0.01% |
23,800
-4,517
| -16% | -$13.7K |
|
2936
enGene Therapeutics
ENGN
$121M
| $70.9K | ﹤0.01% |
15,832
-20,034
| -56% | -$124K |
|
|
YALA
2937
Yalla Group
YALA
$841M
| $70.8K | ﹤0.01% |
13,561
-18,262
| -57% | -$78.6K |
|
2938
Fortress Biotech
FBIO
$97.7M
| $69.9K | ﹤0.01% |
44,799
-9,255
| -17% | -$16.3K |
|
2939
FerroAtlántica
GSM
$757M
| $69.2K | ﹤0.01% |
18,664
-12,444
| -40% | -$48K |
|
|
WW
2940
DELISTED
WW International
WW
| $67.8K | ﹤0.01% |
129,709
-424,015
| -77% | -$368K |
|
|
NSLR
2941
Neostellar Capital Corp
NSLR
$261M
| $67.6K | ﹤0.01% |
+13,597
| New | +$79.1K |
|
|
ATYR
2942
aTyr Pharma
ATYR
$52M
| $67.2K | ﹤0.01% |
22,239
+611
| +3% | +$2.23K |
|
|
BLUE
2943
DELISTED
bluebird bio
BLUE
| $67.1K | ﹤0.01% |
13,745
-5,637
| -29% | -$33.9K |
|
|
CMBM
2944
DELISTED
Cambium Networks
CMBM
| $66.7K | ﹤0.01% |
94,529
-6,955
| -7% | -$6.81K |
|
|
ACB
2945
Aurora Cannabis
ACB
$249M
| $66.3K | ﹤0.01% |
+15,098
| New | +$71.3K |
|
|
ALMS
2946
Alumis Inc
ALMS
$2.98B
| $65.7K | ﹤0.01% |
+10,700
| New | +$62.3K |
|
2947
Enel Chile
ENIC
$6.27B
| $65.5K | ﹤0.01% |
20,025
-3,400
| -15% | -$10.9K |
|
2948
BioAtla
BCAB
$5.46M
| $65.4K | ﹤0.01% |
3,771
+1,067
| +39% | +$22.8K |
|
2949
PepGen
PEPG
$221M
| $64.9K | ﹤0.01% |
+46,194
| New | +$95.1K |
|
2950
Precision BioSciences
DTIL
$233M
| $64.7K | ﹤0.01% |
+13,565
| New | +$69K |
|
Similar funds
John Overdeck's Q1 2025 Portfolio in Review
As of Q1 2025, John Overdeck held 3,617 positions worth $46.8B, up 2% from $45.9B the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
John Overdeck deployed $2.08B of net new capital in Q1 2025, opening 458 new positions and adding to 1,225 existing holdings. Its largest new stake was Advanced Micro Devices: 2,246,952 shares worth $231M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $255M trimmed.
- John Overdeck's largest Q1 2025 buy was Advanced Micro Devices: 2,246,952 shares worth $231M.
- John Overdeck added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $510M increase.
- John Overdeck's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $255M.
- John Overdeck fully exited Coinbase in Q1 2025, selling an estimated $45M.
- John Overdeck's ten largest holdings make up 8.1% of its $46.8B portfolio in Q1 2025.
- John Overdeck opened 458 new positions and closed 452 in Q1 2025.
- John Overdeck's portfolio value rose 2% quarter-over-quarter to $46.8B.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.